News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
News Ouro makes debut with $120m for autoimmune disease TCEs Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
Oncology ASCO 2024 - Matteo Levisetti ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl